After an inspection of its Tokyo facility in November, the US Food and Drug Administration issued a pointed warning letter to Olympus Medical Systems concerning various single-use endoscopes and related accessories that the company manufacturers there.
The FDA’s letter, issued to Olympus on 17 March, accuses Olympus of producing “adulterated” devices, which means the company did not follow good manufacturing practices as required by the Quality System regulation under federal law
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?